NCT04609566

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 161 (actual)
• Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.

Conditions

• Melanoma
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck

Interventions

Type	Name	Description
DRUG	brentuximab vedotin	1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
DRUG	pembrolizumab	200 mg given intravenously every 3 weeks

Timeline

• Start date: 2021-01-26
• Primary completion: 2026-02-03
• Completion: 2026-02-03
• First posted: 2020-10-30
• Last updated: 2026-03-16

Locations

93 sites across 1 country: United States

Regulatory

• FDA-regulated drug study